Primary Aim
To determine whether;
- Donepezil is significantly better than placebo in the management of agitation in
Alzheimer's Disease that has not responded to, or is inappropriate for a standardised
brief psychosocial treatment
Secondary Aims
To determine whether;
- Donepezil has a significant positive or negative impact upon quality of life compared
with placebo
- whether there is a significant difference between Donepezil and placebo with respect to
cognitive performance
- the cost effectiveness of the pharmacological treatment for agitation